Drug profile · INN
doxacurium chloride
NUROMAX
doxacurium chloride (NUROMAX) is a muscle-type nicotinic acetylcholine receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — doxacurium chloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
doxacurium chloride (NUROMAX) is a muscle-type nicotinic acetylcholine receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscle-type nicotinic acetylcholine receptor antagonist
Primary target: Muscle-type nicotinic acetylcholine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is doxacurium chloride?
doxacurium chloride (NUROMAX) is a muscle-type nicotinic acetylcholine receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for doxacurium chloride?
NUROMAX is a marketed brand name for doxacurium chloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of doxacurium chloride?
doxacurium chloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.